Lack of effect of methylphenidate on serum growth hormone (GH), GH- binding protein, and insulin-like growth factor I

Clinical Neuropharmacology

Volumn 20, Issue 3, 1997, Pages 264-269

  Toren, Paz ^a,d   Silbergeld, Aviva ^a   Eldar, Sofia ^a   Laor, Nathaniel ^a,c   Wolmer, Leo ^a   Koren, Sharon ^a   Weitz, Raphael ^b   Inbar, Dov ^b   Reiss, Ahuva ^a   Eshet, Rina ^a   Weizman, Ronit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TEL AVIV COMMUNITY MENTAL HEALTH CENTER   (Israel)

Author keywords

Attention deficit and hyperactivity disorder; Growth hormone; Growth hormone binding protein; Insulin like growth factor I; Methylphenidate

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE BINDING PROTEIN; METHYLPHENIDATE; SOMATOMEDIN C;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; BLOOD LEVEL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; MALE; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

EID: 0030981002     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199706000-00011     Document Type: Article

References (28)

1. Andersen J, Williams S, McGee R, Silva PA. The prevalence of DSM-III disorders in a large sample of pre-adolescent children from the general population. Arch Gen Psychiatry 1487;44:69-81.
2. Bird HR, Canino G, Rubio-Stipec M, et al. Estimates of the prevalence of childhood maladjustment in a community survey in Puerto Rico. Arch Gen Psychiatry 1988;45:1120-6.
3. Shaywitz SE, Shaywitz BA. Increased medication use in attention-deficit hyperactivity disorder: regressive or appropriate [Editorial]? JAMA 1988;260:2270-2.
4. Cantwell DP. Pharmacotherapy of ADD in adolescents: what do we know, where should we go, how should we do it? Psychopharmacol Bull 1985;21:251-7.
5. Wilens TE, Biederman J. The stimulants. Psychiatr Clin North Am 1992;15:191-221.
6. Safer DJ, Krager JM. A survey of medication treatment for hyperactive/inattentive students. JAMA 1988;260:2256-8.
7. Safer D, Allen R, Barr E. Depression of growth in hyperactive children on stimulant drugs. N Engl J Med 1972;287:217-20.
8. Mattes JA, Gittelman R. Growth of hyperactive children on maintenance regimen of methylphenidate. Arch Gen Psychiatry 1983;40:317-21.
9. Gittelman-Klein R, Mannuzza S. Hyperactive boys almost grown up. Arch Gen Psycrhiatry 1988;45:1131-4.
10. Vincent J, Varley CK, Leger P. Effects of methylphenidate on early adolescent growth. Am J Psychiatry 1990;147:501-2.
11. Gittelman-Klein R, Landa B, Mattes JA, Klein DF. Methylphenidate and growth in hyperactive children. Arch Gen Psychiatry 1988;45:1127-30.
12. Gross MD. Growth of hyperkinetic children taking methylphenidate, dextroamphetamine, or imipramine/desipramine. Pediatrics 1976;58:423-31.
13. Aarskog D, Fevang FO, Klove H, Stoa KF, Thorsen T. The effect of the stimulant drugs, dextroamphetamine and methylphenidate, on secretion of growth hormone in hyperactive children. J Pediatr 1977;90:136-9.
14. Shaywitz SE, Hunt RD, Jatlow P, et al. Psychopharmacology of attention deficit disorder: pharmacokinetic, neuroendocrine and behavioral measures following acute and chronic treatment with methylphenidate. Pediatrics 1982;69:688-94.
15. Shaywitz BA, Shaywitz SE, Sebrechts MM, et al. Growth hormone and prolactin response to methylphenidate in children with attention deficit disorder. Life Sci 1990;46:625-33.
16. LeRoith D, Clemmons D, Nissley P, Rechler MM. Insulin-like growth factors in health and disease. Ann Intern Med 1992;116:854-62.
17. Schultz FR, Hayford JT, Wolraich ML, Hintz RL, Thompson RG. Methylphenidate treatment of hyperactive children: effects on the hypothalamic-pituitary-somatomedin axis. Pediatrics 1982;70:987-92.
18. Leung DW, Spencer SA, Cachianes G, et al. Growth hormone receptor and serum binding protein: purification, cloning and expression. Nature 1987;330:537-43.
19. Silbergeld A, Keret R, Selman Amonte A, Klinger B, Laron Z. Serum growth hormone binding protein in Laron syndrome patients and their relatives. In: Laron Z, Parks JS, eds. Lessons from Laron syndrome 1966-1992. Basel: Karger, 1993:160-6 (Pediatric and adolescent endocrinology; vol 24).
20. Baumann G. Growth Hormone-binding proteins: state of the art [Commentary]. J Endocrinol 1994;141:1-6.
21. Goyette CH, Conners CK, Ulrich RF. Normative data on the revised formers parents and teachers rating scales. J Abnorm Child Psychol 1978;6:221-36.
22. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders. 3rd ed, rev (DSM-III-R). Washington, DC: APA, 1987.
23. Orvaschel H, Puig-Antich J. Schedule for affective disorders and schizophernia for school-age children, epidemiologic 4th version. Ft Lauderdale, FL; Nova University, Center for Psychological Study, 1987.
24. Silbergeld A, Lazar L, Erster B, Keret R, Tepper R, Laron Z. Serum growth hormone binding protein activity in neonates, children and young adults: correlation with age, height and weight. Clin Endocrinol 1989;31:295-303.
25. Eshet R, Silbergeld A, Kauli R, Lazar L, Laron Z. GH and GHBP activity and not IGF-1 and its receptor activity express growth velocity reduction during treatment of central precocious puberty by a superactive GNRH analogue. Isr J Med Sci 1994;30:592-5.
26. Solanto MV. Dosage effects of ritalin on cognition. In: Greenhill LL, Osman BB, eds. Ritalin: theory and patient management. New York: Mary Ann Liebert, 1991.
27. Green WH. Sympathomimetic amines and central nervous system stimulants. In: Child and adolescent clinical psychopharmacology. Baltimore, MD: Williams and Wilkins, 1991:61-77.
28. Kanety H, Karasik A, Klinger B, Silbergeld A, Laron Z. Long-term treatment of Laron type dwarfs with insulin-like growth factor-1 increases serum IGFBP-3 in the absence of growth hormone activity. Acta Endocrinol 1993;128:144-9.